Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Dazukibart by Pfizer for Dermatomyositis: Likelihood of Approval
Dazukibart is under clinical development by Pfizer and currently in Phase III for Dermatomyositis. According to GlobalData, Phase III drugs...
Dazukibart by Pfizer for Subacute Cutaneous Lupus Erythematosus (SCLE): Likelihood of Approval
Dazukibart is under clinical development by Pfizer and currently in Phase II for Subacute Cutaneous Lupus Erythematosus (SCLE). According to...
Dazukibart by Pfizer for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE): Likelihood of Approval
Dazukibart is under clinical development by Pfizer and currently in Phase II for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid...
Dazukibart by Pfizer for Cutaneous Lupus Erythematosus: Likelihood of Approval
Dazukibart is under clinical development by Pfizer and currently in Phase II for Cutaneous Lupus Erythematosus. According to GlobalData, Phase...
Dazukibart by Pfizer for Polymyositis: Likelihood of Approval
Dazukibart is under clinical development by Pfizer and currently in Phase III for Polymyositis. According to GlobalData, Phase III drugs...
Dazukibart by Pfizer for Systemic Lupus Erythematosus: Likelihood of Approval
Dazukibart is under clinical development by Pfizer and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Pfizer's Dazukibart?
Dazukibart is a monoclonal antibody commercialized by Pfizer, with a leading Phase III program in Polymyositis. According to Globaldata, it...